Table 2.
Reasons for Switching Nonnucleoside Reverse Transcriptase Inhibitors
| No. (%) of Total Cohorta | |
|---|---|
| Switched from efavirenz to nevirapine (n = 26) | |
| Puberty | 13 (3.1) |
|
| |
| Gynecomastia | 7 (1.7) |
|
| |
| Neuropsychiatric effects | 4 (1.0) |
|
| |
| Out of stock | 2 (0.5) |
|
| |
| Switched from nevirapine to efavirenz (n = 13) | |
| Dermatologic reaction | 5 (1.3)b |
|
| |
| Regimen simplification | 4 (1.0) |
|
| |
| Hepatotoxic effects | 3 (0.8)b |
|
| |
| Emesis | 1 (0.3) |
|
| |
| Not documented | 1 (0.3) |
a
There were 421 patients who started taking efavirenz and 383 who started taking nevirapine.
b
One patient had 2 reasons for the treatment switch.